Clinical Trial

Short Course Radiotherapy Followed by CAPOX and Carrilizumab and Bevacizumab or Cetuximab for the Initial Treatment of Unresectable Metastatic Rectal Cancer

Name: Short Course Radiotherapy Followed by CAPOX and Carrilizumab and Bevacizumab or Cetuximab for the Initial Treatment of Unresectable Metastatic Rectal Cancer — clinical trial record (NCT07059949)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: Union-mRC

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

To evaluate the efficacy and safety of short-course radiotherapy followed by CAPOX and carrilizumab and bevacizumab or cetuximab in the initial treatment of unresectable metastatic rectal cancer

Trial Details

NCT Number	NCT07059949
Lead Sponsor	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Conditions	Unresectable Metastatic Rectal Cancer, CAPOX, Combination of Radioimmunotherapy
Enrollment	80 participants
Start Date	2025-06-30
Primary Completion	2027-01-30 (estimated)
Study Completion	2027-06-30 (estimated)
Updated on ClinicalTrials.gov	2025-07-11